Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 6, 2026VaccineOpen Access

Immunogenicity and safety of a SARS-CoV-2 recombinant vaccine S-268024 booster vaccination versus NVX-CoV2373: Interim results from a phase 3, multicenter, randomized, observer-blind, active-controlled study

View Full Paper
Ask AI
Bookmark
Share

Authors

TNTakashi NakanoKawasaki Medical SchoolSISatoshi IwataTokyo Medical UniversityKOKazunori OishiToyama Institute of Health

Discussion

Loading...

Member takes

Overview

Randomized trial compares immunogenicity and safety of S-268024 booster in vaccinated adults, indicating promising outcomes.

Key Points

  • This research aims to determine the immunogenicity and safety of the S-268024 booster vaccine against NVX-CoV2373.
  • Phase 3, randomized, observer-blind trial
  • Enrolled vaccinated Japanese adults without SARS-CoV-2 history
  • Evaluated noninferiority and safety outcomes
  • Immunogenicity population: 733 participants; S-268024 group: 368, NVX-CoV2373 group: 365
  • GMT ratio of S-268024 to NVX-CoV2373 was 1.79 (95% CI: 1.52-2.12)
  • S-268024 had a seroresponse rate difference of 7.9% (95% CI: 1.3%-14.4%) and a higher adverse event rate (92.4% vs 77.5%)

Cite This Study

Nakano et al. (2026) studied this question.

synapsesocial.com/papers/6a4b453d997070ff83b5b097https://doi.org/10.1016/j.vaccine.2026.128871
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Immunogenicity and safety of booster dose of S-268019-b or BNT162b2 in Japanese participants: An interim report of phase 2/3, randomized, observer-blinded, noninferiority study2022 · 21 citations
  2. 2Safety and immunogenicity of a booster dose of S-268019-b: Interim findings of a Phase 3, open-label clinical study in Japan2023 · 5 citations
  3. 3Safety and immunogenicity of the NVX-CoV2373 vaccine as a booster in adults previously vaccinated with the BBIBP-CorV vaccine2024 · 8 citations
  4. 4A phase 3 randomized controlled trial of a COVID-19 recombinant vaccine S-268019-b versus ChAdOx1 nCoV-19 in Japanese adults2024 · 6 citations
  5. 5One-year follow-up of the immunogenicity and safety of a first and second booster dose of the NVX-CoV2373 (TAK-019) vaccine in healthy Japanese adults who had previously received a primary series of COVID-19 mRNA vaccine: Final report of a phase 3 open-label trial2025